While IL-15 engineering alone is expected to increase iNK yield and enhance NK cell activity, CAR engineering likely further augments the selective and sustained cytotoxicity of IL-15–expressing iNK cells against tumor cells, as demonstrated by the superior antitumor efficacy of CAR-IL-15–expressing cord blood NK cells compared to those expressing IL-15 alone (37). This evidence concerns the gene IL15 and neoplasm.